211 related articles for article (PubMed ID: 27377059)
21. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
Quera R; O'Sullivan K; Quigley EM
Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
[TBL] [Abstract][Full Text] [Related]
22. Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.
Kastelein F; van Olphen SH; Steyerberg EW; Spaander MC; Bruno MJ;
Gut; 2016 Apr; 65(4):548-54. PubMed ID: 25903690
[TBL] [Abstract][Full Text] [Related]
23. Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis.
Eusebi LH; Cirota GG; Zagari RM; Ford AC
Gut; 2021 Mar; 70(3):456-463. PubMed ID: 32732370
[TBL] [Abstract][Full Text] [Related]
24. Incidence of adenocarcinoma and mortality in patients with Barrett's oesophagus diagnosed between 1976 and 1986: implications for endoscopic surveillance.
Rana PS; Johnston DA
Dis Esophagus; 2000; 13(1):28-31. PubMed ID: 11005328
[TBL] [Abstract][Full Text] [Related]
25. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
[TBL] [Abstract][Full Text] [Related]
26. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
27. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation.
Morris CD; Byrne JP; Armstrong GR; Attwood SE
Br J Surg; 2001 Oct; 88(10):1357-62. PubMed ID: 11578292
[TBL] [Abstract][Full Text] [Related]
28. Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme. Gruppo Operativo per lo Studio delle Precancerosi Esofagee (GOSPE).
Ferraris R; Bonelli L; Conio M; Fracchia M; Lapertosa G; Aste H
Eur J Gastroenterol Hepatol; 1997 Sep; 9(9):881-5. PubMed ID: 9355787
[TBL] [Abstract][Full Text] [Related]
29. Barrett's oesophagus: a review of costs of the illness.
Arguedas MR; Eloubeidi MA
Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670
[TBL] [Abstract][Full Text] [Related]
30. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
[TBL] [Abstract][Full Text] [Related]
31. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
[TBL] [Abstract][Full Text] [Related]
32. Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
Gatenby P; Caygill C; Wall C; Bhatacharjee S; Ramus J; Watson A; Winslet M
World J Gastroenterol; 2014 Jul; 20(28):9611-7. PubMed ID: 25071359
[TBL] [Abstract][Full Text] [Related]
33. External validation of a model to determine risk of progression of Barrett's oesophagus to neoplasia.
Kunzmann AT; Thrift AP; Johnston BT; McManus DT; Gavin AT; Turkington RC; Coleman HG
Aliment Pharmacol Ther; 2019 May; 49(10):1274-1281. PubMed ID: 30950101
[TBL] [Abstract][Full Text] [Related]
34. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota.
Conio M; Cameron AJ; Romero Y; Branch CD; Schleck CD; Burgart LJ; Zinsmeister AR; Melton LJ; Locke GR
Gut; 2001 Mar; 48(3):304-9. PubMed ID: 11171817
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study.
Anderson LA; Watson RG; Murphy SJ; Johnston BT; Comber H; Mc Guigan J; Reynolds JV; Murray LJ
World J Gastroenterol; 2007 Mar; 13(10):1585-94. PubMed ID: 17461453
[TBL] [Abstract][Full Text] [Related]
36. Surveillance for Barrett's oesophagus: results from a programme in Northern Ireland.
Murphy SJ; Dickey W; Hughes D; O'Connor FA
Eur J Gastroenterol Hepatol; 2005 Oct; 17(10):1029-35. PubMed ID: 16148547
[TBL] [Abstract][Full Text] [Related]
37. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years.
Hage M; Siersema PD; van Dekken H; Steyerberg EW; Dees J; Kuipers EJ
Scand J Gastroenterol; 2004 Dec; 39(12):1175-9. PubMed ID: 15742992
[TBL] [Abstract][Full Text] [Related]
38. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
Wong T; Tian J; Nagar AB
Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
[TBL] [Abstract][Full Text] [Related]
39. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
[TBL] [Abstract][Full Text] [Related]
40. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study.
de Jonge PJ; van Blankenstein M; Looman CW; Casparie MK; Meijer GA; Kuipers EJ
Gut; 2010 Aug; 59(8):1030-6. PubMed ID: 20639249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
